iBio, Inc. Overview
Pro stress-test →iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases, combining proprietary 3D modeling with innovative drug discovery platforms to create breakthrough antibody treatments. The company has $52.7M in cash as of December 2025 with runway extended into Q3 FY2028.
Strategic Profile
Pro stress-test →iBio has two lead programs: IBIO-610, its activin E antibody, and IBIO-600, its myostatin antibody, both advancing toward human clinical trials with IBIO-610 on track for early 2027 and IBIO-600 planned for H1 2026. IBIO-610 has demonstrated a predicted human half-life of up to 100 days supporting potential dosing as infrequently as twice per year, positioning it as a first-in-class obesity therapeutic with distinct advantages over current GLP-1 treatments.
Competitive Landscape
Pro stress-test →iBio competes in the obesity and cardiometabolic therapeutics space against established GLP-1 agonists and emerging antibody platforms. Key differentiation lies in long-acting antibody format (twice-yearly dosing vs. weekly injections) and fat-selective weight loss mechanism. Main competitors include Novo Nordisk (Ozempic/Wegovy), Eli Lilly (Mounjaro), and emerging obesity biotech startups. iBio's AI-driven platform and 3D modeling approach provide platform durability.
Industry Context
iBio, Inc. operates in Biopharmaceutical / Precision Medicine - Obesity and Cardiometabolic Therapeutics.
Key facts
Founded: 2008 · Headquarters: San Diego, US · Employees: 20 · Revenue: $400K